马瓦卡门在有症状的患者中,这些患者对先前的阻塞性多变性心肌病的先进疗法有抗性
Daniele Massera1, Elizabeth Adlestein1, Sumar Frejat1
1Hypertrophic Cardiomyopathy Program, Leon H. Charney Division of Cardiology NYU Langone Health New York NY USA.
Journal of the American Heart Association
|July 17, 2025
概括
马瓦卡门有效治疗阻塞性多变性心肌病变 (oHCM) 在患者耐药之前的疗法. 这项研究表明,在这个具有挑战性的患者群体中,mavacamten可以改善症状并减少左心室外流阻塞.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 医学治疗学 医学治疗学
背景情况:
- 在之前先进治疗过的阻塞性缩性心肌病 (oHCM) 患者中,mavacamten的临床效用尚未得到充分证实.
- oHCM是一种以左心室外流阻塞 (LVOTO) 为特征的疾病.
研究的目的:
- 评估oHCM和LVOTO患者中mavacamten的疗效和安全性,这些患者之前接受过先进治疗.
- 评估使用mavacamten治疗的患者的临床和心声学结局.
主要方法:
- 对115名患有oHCM的患者进行了回顾性分析,这些患者接受了至少8周的mavacamten治疗.
- 患者根据先前的治疗进行了分类:迪索皮拉米德,隔膜肌切除术,酒精隔膜切除,双室节奏,或主动脉置换后的LVOTO.
主要成果:
- 马瓦卡门治疗导致纽约心脏协会 (P<0.0001) 课程显著改善 (P<0.0001).
- 在先前接受治疗和未接受治疗的组中,最大的LVOTO梯度大大降低了 (从~100 mmHg到~12 mmHg).
- 左心室缩功能障碍发生在10%的患者中,两组之间没有显著差异.
结论:
- 马瓦卡门证明了oHCM患者对症状性LVOTO的安全性和有效性,这些患者对先进疗法不耐药.
- 它在发生LVOTO的患者中是有效的,大动脉置换后.
相关概念视频
01:29Cardiomyopathy V: Interprofessional Care
37
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
37
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
54
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
54
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
36
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
36
01:30Cardiomyopathy II: Dilated Cardiomyopathy
24
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
24
01:26Mitral Stenosis III: Medical Management
27
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
27
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
513
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
513